Although these novel compounds are quite encouraging and offer new hope for NSCLC patients carrying the KrasG12C mutation, Kras gain-of-function mutations in NSCLC also include KrasG12D and KrasG12V [179,180], which are either not or less preferentially targeted by the above-mentioned compounds [177,178]. Here, KRAS is linked to non-small cell lung carcinoma.